Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Prof. Khaydar Yunusov at Institute of Polymer Chemistry and Physics Uzbekistan Academy of Sciences, Uzbekistan.

Prof. Khaydar Yunusov is a distinguished polymer chemist from Uzbekistan with extensive expertise in nanotechnology, cellulose chemistry, and biomaterials. Since 2007, he has held key research and leadership roles at the Institute of Polymer Chemistry and Physics, contributing significantly to polymer-based biomedical innovations. 💊 He holds a Doctor of Science and leads groundbreaking projects on nanostructured antibacterial films, antiviral eye medications, and burn treatments. 📘 With several patents, international collaborations 🌍, and editorial roles in leading journals, Prof. Yunusov is a pioneering force in sustainable polymer research and nanomedical applications.

Publication Profile 

Orcid

Education

Prof. Khaydar Yunusov began his academic journey at the Tashkent Chemical Technological Institute, earning a Bachelor’s degree in Chemistry (2006) and a Master’s in Cellulose, Paper Chemistry, and Technology (2008). 📘 Driven by scientific excellence, he pursued a Doctor of Science in Technical Sciences (2009–2016), focusing on advanced polymer research. Since 2018, he has served as a Senior Scientific Researcher in Nanochemistry, Nanophysics, and Nanotechnology. 🧪 His research delves into nanostructured bactericidal preparations based on cellulose and its derivatives, emphasizing synthesis, properties, and production technologies. 🧬 His academic background provides a solid foundation for pioneering innovations in polymer science.

Experience

Prof. Khaydar Yunusov has cultivated a rich professional career in polymer science, beginning in 2007 as a researcher at the Institute of Polymer Chemistry and Physics, Uzbek Academy of Sciences, Tashkent. 📍 Over the years, he advanced through roles including junior researcher, senior researcher, and project manager, earning his Doctor of Science along the way. 🔬 His expertise spans polymer and cellulose chemistry, nanotechnology, and biomaterials. From 2019 to 2023, he served as a lab and project manager, driving innovation in nanostructured materials. 💼 Prof. Yunusov’s professional path reflects unwavering dedication to scientific discovery and technological advancement.

Research Focus 

Prof. Khaydar Yunusov is a pioneering scientist whose research spans polymer chemistry, cellulose technology, and nanochemistry. His core focus lies in designing biocompatible nanomaterials 🧫 such as nanostructured drug delivery systems, microneedles, hydrogels, and functional films for medical applications 🎯. He actively explores biodegradable polymers, nanoparticle synthesis (silver, selenium, zinc oxide), and antimicrobial and anticancer therapies 💊. His work intersects biotechnology, materials science, and pharmaceutical engineering, advancing targeted treatments and regenerative medicine 🧠🦠. With numerous high-impact publications, Prof. Yunusov is shaping the future of smart biomaterials and sustainable polymeric solutions.

Publication Top Notes

  • A red cell membrane-camouflaged nanoreactor for enhanced starvation/chemodynamic/ion interference therapy for breast cancer
  • A three-dimensional printable conductive composite dressing for accelerating wound healing under electrical stimulation
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management ( vol 12, pg 1064, 2024)
  • Fabrication of hollow microneedles with double-layer shell structure for rapid and prolonged local anesthesia
  • Homemade isothermal amplification-initiated Cas14a assay for rapid quantitative detection of aquatic RNA virus gene with no PAM
  • Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment
  • Real-time microbial growth curve (RMGC) system: an improved microplate reader with a graphical interface for automatic and high-throughput monitoring of microbial growth curves
  • Two-directions mechanical strength and high-barrier mechanisms of cellulose nanocrystal- based hybrids reinforced packaging with nacre-mimetic structure
  • Physico-chemical characteristics of dialdehyde carboxymethylcellulose/sericin graft copolymer
  • Synthesis, Characterization, and Cytotoxic Activity of Stable Selenium Nanoparticles‐Incorporated Carboxymethylcellulose Solution
  • Impact of cellulose supramolecular structure on its carboxymethylation reaction activity
  • Advances in the formation and properties of nanofiber biomaterials from polyvinyl alcohol/carboxymethylcellulose/nanosilver systems for medical applications
  • Obtaining Dialdehyde Carboxymethylcellulose Through Microwave Treatment
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Dr. IOANNIS VAMVAKARIS, IATROPOLIS, Greece

Dr. Ioannis Vamvakaris is a distinguished Greek pathologist specializing in thoracic pathology. 🫁 He earned his MSc in Thoracic Oncology in 2013 and PhD in 2018 from Athens School of Medicine. 🎓 Since 2019, he has led the Pathology Department at Sotiria General Hospital. 🏥 He’s authored over 200 publications 📚 and co-developed Greece’s first AI software for pathology. 🤖 A reviewer for top journals (Elsevier, MDPI), he actively collaborates on global research in cancer, organoids, proteomics, and microbiome. 🌍 Recognized with the 2024 Best Researcher Award 🏆 and Sigma Xi membership, Dr. Vamvakaris continues to shape medical science with dedication and innovation.

Publication Profile

Google Scholar

Education

Dr. Ioannis Vamvakaris is a highly accomplished pathologist who began his medical journey at Sotiria General Hospital in Athens 🏥. Since 2008, he has served as a consultant in the pathology department, demonstrating unwavering dedication to thoracic pathology 🫁. He earned his MSc in Thoracic Oncology in 2013 and completed his PhD in 2018 from the Athens School of Medicine 🎓. Dr. Vamvakaris also pursued specialized training in Patient-Crisis-Emergency Management at the Berlin School of Economics 🇩🇪. His academic growth and professional excellence highlight his strong commitment to advancing medical knowledge and enhancing patient care globally 🌍.

Awards

Dr. Ioannis Vamvakaris has earned prestigious honors in recognition of his exceptional contributions to pathology and oncology research 🔬. In 2024, he was presented with the Best Researcher Award at the International Research Awards on Oncology and Cancer Research 🧬. That same year, he was inducted as an Associate Member of Sigma Xi 🧠—a globally respected scientific research honor society that recognizes excellence through nomination only. Additionally, he received the Trusted Reviewer Certificate in 2023 📄, reflecting his outstanding commitment to scientific publishing and peer evaluation. These accolades underscore his leadership and integrity in medical science 🌟.o

Research Focus

Dr. Ioannis Vamvakaris is a leading expert in thoracic pathology, with a strong research focus on lung cancer, molecular oncology, and immunopathology 🔬. His studies span non-small cell lung cancer (NSCLC), checkpoint inhibitor-induced sarcoidosis, and PD-1/PD-L1 immune responses 🧬. His collaborative work explores liquid biopsy biomarkers, xenograft models, and AI-assisted diagnostics 🤖. Passionate about translational research, he contributes to genomics, proteomics, fibrosis, and epigenetics in thoracic malignancies. His multidisciplinary efforts bridge clinical pathology and personalized medicine, advancing early diagnosis and targeted therapies 💉. Dr. Vamvakaris’ research enriches global understanding of lung diseases and thoracic oncology 🌍.

Publication Top Notes

Sarcoidosis-like reactions induced by checkpoint inhibitors

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Epithelial–mesenchymal transition in non small-cell lung cancer

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy

Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic …

An immunohistochemical evaluation of the proteins W nt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

Pulmonary blastoma: a comprehensive overview of a rare entity

Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early …

Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Published on by Top Pharmaceutical

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Dr. Daniel Bikle, University of California San Francisoco, United States

Dr. Daniel Bikle 🧬 is a distinguished physician-scientist specializing in endocrinology and bone metabolism. He earned his A.B. magna cum laude from Harvard 🎓 and M.D. from the University of Pennsylvania 🏥, followed by a Ph.D. in Biochemistry. Currently a Professor of Medicine and Dermatology at the University of California, San Francisco 🌉, he has held key research and clinical roles since the 1970s. Dr. Bikle is renowned for his groundbreaking work on vitamin D and bone health ☀️🦴. He has received numerous awards 🏆 and serves on editorial boards and international scientific committees worldwide 🌍.

Publication Profile

Orcid

Education

Dr. Daniel Bikle’s impressive academic journey began at Harvard University 🎓, where he earned his A.B. magna cum laude in Biochemical Sciences in 1965. He then pursued his medical degree (M.D.) at the University of Pennsylvania School of Medicine 🏥, graduating in 1969. Following medical school, he completed an internship and residency at Peter Bent Brigham Hospital in Boston 🏨 from 1969 to 1971, gaining valuable clinical experience. Dr. Bikle deepened his scientific expertise by earning a Ph.D. in Biochemistry at the University of Pennsylvania in 1974 🔬, laying a strong foundation for his distinguished career in medicine and research.

Awards

Dr. Daniel Bikle has received numerous prestigious honors throughout his career 🏅. Starting with the Harvard Honorary Scholarship 🎓 in 1961 and multiple National Science Foundation Fellowships 🔬 during the 1960s, he earned several prizes at Harvard and the University of Pennsylvania, including the Henderson Memorial Prize 🏆 and Horatio C. Wood Prize in Pharmacology 💊. He was awarded fellowships by NIH and professional societies such as the American College of Physicians and Molecular Medicine 🩺. His later accolades include the Boy Frame Award 🦴 in 2007 and the Louis V Avioli Founders Award in 2016, recognizing his excellence in bone and mineral research.

Research Focus

Dr. Daniel Bikle’s research primarily focuses on vitamin D biology, its metabolism, and its critical role in bone health, skin physiology, and immune function 🦴☀️🧬. His extensive work explores vitamin D receptor actions, calcium signaling, and their impact on processes like wound healing and stem cell behavior 🩹🧪. He investigates vitamin D’s role in diseases such as long COVID and lymphoma, and how it influences cellular differentiation and mineral metabolism 🦠💉. Dr. Bikle also studies the molecular mechanisms of vitamin D in skin and bone, making his research essential for endocrinology, dermatology, and metabolic bone disease fields.

Publication Top Notes

Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding

Vitamin D and Long COVID: Is There a Role in Prevention or Treatment?

Mediator 1 ablation induces enamel-to-hair lineage conversion in mice through enhancer dynamics

Mediator 1 ablation induces enamel-to-hair lineage conversion through enhancer dynamics

Role of vitamin D and calcium signaling in epidermal wound healing

Ligand‐Independent Actions of the Vitamin D Receptor: More Questions Than Answers

Decreased Calcium-Sensing Receptor Expression Controls Calcium Signaling and Cell-To-Cell Adhesion Defects in Aged Skin

Introduction: Special Issue on Vitamin D Dedicated to the Memory of Anthony W Norman

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status

Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair

Salma Khan | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer SubtypesProteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Dr. Pilar Hernandez Jimenez, Hospital Universitario 12 de Octubre, Spain

Dr. María del Pilar Hernández Jiménez 🩺🔬 is a specialist in internal medicine with a focus on infectious diseases. She earned her M.D. from the Universidad de Alcalá (2011) and completed her MIR in Internal Medicine at HU 12 de Octubre (2013-2018). With expertise in HIV, tropical diseases, and antimicrobial resistance, she has contributed to multiple research projects, publishing 21 indexed articles (h-index 9). Currently, she is a Río Hortega researcher at Instituto de Salud Carlos III and a consultant at HU 12 de Octubre. Her doctoral thesis (2024) explores multidrug-resistant Pseudomonas aeruginosa.

Publication Profile

orcid

Education

Dr. Pilar Hernandez Jimenez 🎓 earned her Ph.D. in Health Sciences (2024) from Universidad Complutense de Madrid. She holds a Master’s in Infectious Diseases in Immunocompromised Patients 🦠 and has pursued multiple postgraduate specializations in infectious diseases, tropical medicine 🌍, and HIV 🏥. Her expertise spans critical areas of global health, focusing on combating infectious diseases and improving patient outcomes. With a strong academic foundation and extensive clinical knowledge, Dr. Hernandez Jimenez is dedicated to advancing research and medical practices in infectious disease management, contributing significantly to the field of immunocompromised patient care.

Experience

Dr. Pilar Hernandez Jimenez 🏥 currently serves at Instituto de Salud Carlos III and Hospital Universitario 12 de Octubre, where she plays a vital role in infectious disease research and hospital consultations. With extensive experience in leading studies on infectious diseases 🦠, she has contributed significantly to COVID-19 research 🦠, HIV studies 🏳️‍🌈, and infection management in immunocompromised patients 🤝. Her work bridges clinical practice and research, enhancing patient care and public health strategies. Through collaboration with top medical institutions, Dr. Hernandez Jimenez continues to make a meaningful impact on global health and infectious disease management.

International Exposure

Dr. Pilar Hernandez Jimenez 🌍 has gained extensive international exposure through Erasmus and MIR training in Spain 🇪🇸 and France 🇫🇷, enriching her expertise in infectious diseases. Her global collaborations extend to Brazil 🇧🇷, where she conducted research at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado 🦠, contributing to advancements in tropical medicine and infectious disease management. These international experiences have allowed her to engage with diverse healthcare systems, collaborate with leading researchers, and enhance her medical practice on a global scale. Dr. Hernandez Jimenez continues to foster cross-border medical innovation and research excellence.

Research Focus

Dr. María del Pilar Hernández-Jiménez is a distinguished infectious disease researcher 🦠 specializing in prosthetic joint infections, multidrug-resistant bacteria, and antimicrobial treatments 💊. Her research focuses on periprosthetic infections, Pseudomonas aeruginosa, carbapenemase-producing Klebsiella pneumoniae, and infections in immunocompromised and transplant patients 🏥. She has contributed significantly to clinical microbiology, antimicrobial resistance, and infection control 📊. Dr. Hernández-Jiménez’s work extends to COVID-19-related infections and innovative treatments for latent tuberculosis in transplant recipients 🌍. Her extensive collaborations and impactful publications highlight her global influence in infectious disease research 🔬.

Publication Top Notes

Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.